One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.
Lorraine M. Cherry, PhD
Advertisement
Articles by Lorraine M. Cherry, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5